Steroid-binding G-protein-coupled receptors: New drug discovery targets for old ligands

Expert Opinion on Drug Discovery

Volumn 1, Issue 2, 2006, Pages 137-150

  Prossnitz, Eric R ^a,b   Arterburn, Jeffrey B ^d   Edwards, Bruce S ^a,b   Sklar, Larry A ^a,b   Oprea, Tudor I ^b,c  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d NEW MEXICO STATE UNIVERSITY   (United States)

Author keywords

biomolecular screening; drug discovery; estrogen; G protein coupled receptors; GPR30; steroids; virtual screening

Indexed keywords

EID: 33750985337     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.1.2.137     Document Type: Review

References (96)

1. THOMAS T, GALLO MA, THOMAS TJ: Estrogen receptors as targets for drug development for breast cancer, osteoporosis and cardiovascular diseases. Curr. Cancer Drug Targets (2004) 4(6):483-499.
2. TAVANI A, LA VECCHIA C: The adverse effects of hormone replacement therapy. Drugs Aging (1999) 14(5):347-357.
3. SENKUS-KONEFKA E, KONEFKA T, JASSEM J: The effects of tamoxifen on the female genital tract. Cancer Treat. Rev. (2004) 30(3):291-301.
4. HENKE BR, HEYER D: Recent advances in estrogen receptor modulators. Curr. Opin. Drug. Discov. Devel. (2005) 8(4):437-448.
5. KNOX AJ, MEEGAN MJ, LLOYD DG: Estrogen receptors: molecular interactions, virtual screening and future prospects. Curr. Top. Med. Chem. (2006) 6(3):217-243.
6. FILARDO EJ, THOMAS P: GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol. Metab. (2005) 16(8):362-367.
7. REVANKAR CM, CIMINO DF, SKLAR LA, ARTERBURN JB, PROSSNITZ ER: A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science (2005) 307(5715):1625-1630.
8. OLAH M, BOLOGA CG, OPREA TI: Strategies for compound selection. Curr. Drug Discov. Tech. (2004) 1:211-220.
9. CONGREVE M, MURRAY CW, BLUNDELL TL: Structural biology and drug discovery. Drug Discov. Today (2005) 10(13):895-907.
10. OPREA TI: Virtual screening in lead discovery: a viewpoint. Molecules (2002) 751-62.
11. STOERMER MJ: Current status of virtual screening as analysed by target class. Med. Chem. (2006) 289-112.
12. MESTRES J: Virtual screening: a real screening complement to high-throughput screening. Biochem. Soc. Trans. (2002) 30(4):797-799.
13. ALVAREZ J, SHOICHET B: Virtual screening in drug discovery. CRC Press, Boca Raton, USA (2005).
14. COUSE JF, KORACH KS: Estrogen receptor null mice: what have we learned and where will they lead us? Endoc. Rev. (1999) 20(3):358-417.
15. FRANK GR: Role of estrogen and androgen in pubertal skeletal physiology. Med. Pediatr. Oncol. (2003) 41(3):217-221.
16. BAKER L, MELDRUM KK, WANG M et al.: The role of estrogen in cardiovascular disease. J. Surg. Res. 2003 115(2): 325-344.
17. TORAN-ALLERAND CD: Minireview: a plethora of estrogen receptors in the brain: where will it end? Endocrinology (2004) 145(3):1069-1074.
18. KOVACS EJ, MESSINGHAM KA, GREGORY MS: Estrogen regulation of immune responses after injury. Mol. Cell. Endocrinol. (2002) 193(1-2):129-135.
19. HANSTEIN B, DJAHANSOUZI S, DALL P, BECKMANN MW, BENDER HG: Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer. Eur. J. Endocrinol. (2004) 150(3):243-255.
20. ALI S, COOMBES RC: Estrogen receptor in human breast cancer: occurrence and significance. J. Mammary Gland Biol. Neoplasia (2000) 5(3):271-281.
21. OSOSKI AL, KENNELLY EJ: Phytoestrogens: a review of the present state of research. Phytother. Res. (2003) 17(8):845-869.
22. STAREK A: Estrogens and organochlorine xenoestrogens and breast cancer risk. Int. J. Occup. Med. Environ. Health (2003) 16(2):113-124.
23. JACOBS MN, LEWIS DF: Steroid hormone receptors and dietary ligands: a selected review. Proc. Nutr. Soc. (2002) 61(1):105-122.
24. MITKA M: CDC resource focuses on DES exposure. JAMA (2003) 289(13):1624.
25. PALMLUND I: Exposure to a xenoestrogen before birth: the diethylstilbestrol experience. J. Psychosom. Obstet. Gynaecol. (1996) 17(2):71-84.
26. SINGLETON DW, KHAN SA: Xenoestrogen exposure and mechanisms of endocrine disruption. Front. Biosci. (2003) 8:s110-118.
27. JENKINS EV, DESOMBRE ER: Estrogen-receptor interactions. Science (1973) 182126-182134.
28. KUIPER GG, ENMARK E, PELTO-HUIKKO M, NILSSON S, GUSTAFSSON JA: Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA (1996) 93(12):5925-5930.
29. KUIPER GG, CARLSSON B, GRANDIEN K et al.: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology (1997) 138(3):863-870.
30. DECHERING K, BOERSMA C, MOSSELMAN S: Estrogen receptors and : two receptors of a kind? Curr. Med. Chem. (2000) 7(5):561-576.
31. HEWITT SC, KORACH KS: Oestrogen receptor knockout mice: roles for oestrogen receptors and in reproductive tissues. Reproduction (2003) 125(2):143-149.
32. TORAN-ALLERAND CD, GUAN X, MACLUSKY NJ et al.: ER-x: a novel, plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury. J. Neurosci. (2002) 22(19):8391-8401.
33. LI L, HAYNES MP, BENDER JR: Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc. Natl. Acad. Sci. USA (2003) 100(8):4807-4812.
34. ACCONCIA F, ASCENZI P, FABOZZI G, VISCA P, MARINO M: S-palmitoylation modulates human estrogen receptor-functions. Biochem. Biophys. Res. Commun. (2004) 316(3): 878-883.
35. RAZANDI M, PEDRAM A, LEVIN ER: Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. Mol. Endocrinol. (2000) 14(9):1434-1447.
36. RAZANDI M, PEDRAM A, PARK ST, LEVIN ER: Proximal events in signaling by plasma membrane estrogen receptors. J. Biol. Chem. (2003) 278(4):2701-2712.
37. GOVIND AP, THAMPAN RV: Membrane associated estrogen receptors and related proteins: localization at the plasma membrane and the endoplasmic reticulum. Mol. Cell. Biochem. (2003) 253(1-2):233-240.
38. KELLY MJ, LEVIN ER: Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol. Metab. (2001) 12(4):152-156.
39. LEVIN ER: Cell localization, physiology, and nongenomic actions of estrogen receptors. J. Appl. Physiol. (2001) 91(4):1860-1867.
40. LEVIN ER: Cellular functions of plasma membrane estrogen receptors. Steroids (2002) 67(6): 471-475.
41. HALL JM, COUSE JF, KORACH KS: The multifaceted mechanisms of estradiol and estrogen receptor signaling. J. Biol. Chem. (2001) 276(40):36869-36872.
42. HO KJ, LIAO JK: Nonnuclear actions of estrogen. Arterioscler. Thromb. Vasc. Biol. (2002) 22(12):1952-1961.
43. O'DOWD BF, NGUYEN T, MARCHESE A et al.: Discovery of three novel G-protein-coupled receptor genes. Genomics (1998) 47(2):310-313.
44. OWMAN C, BLAY P, NILSSON C, LOLAIT SJ: Cloning of human cDNA encoding a novel heptahelix receptor expressed in burkitt's lymphoma and widely distributed in brain and peripheral tissues. Biochem. Biophys. Res. Commun. (1996) 228(2):285-292.
45. TAKADA Y, KATO C, KONDO S, KORENAGA R, ANDO J: Cloning of cDNAs encoding G protein-coupled receptor expressed in human endothelial cells exposed to fluid shear stress. Biochem. Biophys. Res. Commun. (1997) 240(3):737-741.
46. CARMECI C, THOMPSON DA, RING HZ, FRANCKE U, WEIGEL RJ: Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics (1997) 45(3):607-617.
47. FILARDO EJ, QUINN JA, BLAND KI, FRACKELTON AR Jr: Estrogen-induced activation of ERK-1 and ERK-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of hb-EGF. Mol. Endocrinol. (2000) 14(10):1649-1660.
48. FILARDO EJ, QUINN JA, FRACKELTON AR Jr, BLAND KI: Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and camp-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol. Endocrinol. (2002) 16(1):70-84.
49. KANDA N, WATANABE S: 17α-estradiol inhibits oxidative stress-induced apoptosis in keratinocytes by promoting Bcl-2 expression. J. Invest. Dermatol. (2003) 121(6):1500-1509.
50. KANDA N, WATANABE S: 17α-estradiol stimulates the growth of human keratinocytes by inducing cyclin D2 expression. J. Invest. Dermatol. (2004) 123(2):319-328.
51. KANDA N, WATANABE S: 17α-estradiol enhances the production of nerve growth factor in THP-1-derived macrophages or peripheral blood monocyte-derived macrophages. J. Invest. Dermatol. (2003) 121(4):771-780.
52. YLIKOMI T, VIENONEN A, AHOLA TM: G protein-coupled receptor 30 down-regulates cofactor expression and interferes with the transcriptional activity of glucocorticoid. Eur. J. Biochem. (2004) 271(21):4159-4168.
53. THOMAS P, PANG Y, FILARDO EJ, DONG J: Identity of an estrogen membrane receptor coupled to a G-protein in human breast cancer cells. Endocrinology (2005) 146(2):624-632.
54. YOO JY, LESSOR T, HAMBURGER AW: Inhibition of cell proliferation by 17α-estradiol and heregulin beta1 in estrogen receptor negative human breast carcinoma cell lines. Breast Cancer Res. Treat. (1998) 51(1):71-81.
55. BROOKS SC, LOCKE ER, SOULE HD: Estrogen receptor in a human cell line (mcf-7) from breast carcinoma. J. Biol. Chem. (1973) 248(17):6251-6253.
56. BRZOZOWSKI AM, PIKE AC, DAUTER Z et al.: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (1997) 389(6652):753-758.
57. SHIAU AK, BARSTAD D, LORIA PM et al.: The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell (1998) 95(7):927-937.
58. SHAO D, BERRODIN TJ, MANAS E et al.: Identification of novel estrogen receptor alpha antagonists. J. Steroid Biochem. Mol. Biol (2004) 88(4-5):351-360.
59. ZHAO L, BRINTON RD: Structure-based virtual screening for plant-based erbeta-selective ligands as potential preventative therapy against age-related neurodegenerative diseases. J. Med. Chem. (2005) 48(10): 3463-3466.
60. JOHNSON MA, MAGGIORA GM: Concepts and applications of molecular similarity. Wiley-VCH, New York, USA (1990).
61. TANIMOTO TT: Non-linear model for a computer assisted medical diagnostic procedure. Trans. N Y Acad. Sci. (1961) 23:576-580.
62. TVERSKY A: Features of similarity. Psychol. Rev. (1977) 84:327-352.
63. PASTOR M, CRUCIANI G, MCLAY I, PICKETT S, CLEMENTI S: Grid-independent descriptors (grind): a novel class of alignment-independent three-dimensional molecular descriptors. J. Med. Chem. (2000) 43(17): 3233-3243.
64. JACKSON JE: A users guide to principal components. Wiley-VCH, New York, USA (1991).
65. DURANT JL, LELAND BA, HENRY DR, NOURSE JG: Reoptimization of MDL keys for use in drug discovery. J. Chem. Inf. Comput. Sci. (2002) 42(6):1273-1280.
66. GRANT JA, GALLARDO MA, PICKUP BT: A fast method of molecular shape comparison: A simple application of a Gaussian description of molecular shape. J. Comput. Chem. (1996) 171653-171666.
67. BOSTROM J, GREENWOOD JR, GOTTFRIES J: Assessing the performance of omega with respect to retrieving bioactive conformations. J. Mol. Graph. Model (2003) 21(5):449-462.
68. GOODFORD PJ: A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. (1985) 28(7):849-857.
69. CARLSON KE, COPPEY M, MAGDELENAT H, KATZENELLENBOGEN JA: Receptor binding of NBD-labeled fluorescent estrogens and progestins in whole cells and cell-free preparations. J. Steroid Biochem. (1989) 32(3):345-355.
70. FRENCH AN, WILSON SR, WELCH MJ, KATZENELLENBOGEN JA: A synthesis of 7 α-substituted estradiols: synthesis and biological evaluation of a 7 α-pentyl-substituted bodipy fluorescent conjugate and a fluorine-18-labeled 7 α-pentylestradiol analog. Steroids (1993) 58(4):157-169.
71. KIM SH, TAMRAZI A, CARLSON KE, DANIELS JR, LEE IY, KATZENELLENBOGEN JA: Estrogen receptor microarrays: subtype-selective ligand binding. J. Am. Chem. Soc. (2004) 126(15):4754-4755.
72. NELSON K, PAVLIK EJ, VAN NAGELL JR Jr., HANSON MB, DONALDSON ES, FLANIGAN RC: Estrogenicity of coumestrol in the mouse: fluorescence detection of interaction with estrogen receptors. Biochemistry (Mosc.) (1984) 23(12):2565-2572.
73. KATZENELLENBOGEN JA, CARLSON KE, BINDAL RD, NEELEY RL, MARTIN PM, MAGDELENAT HP: Fluorescence-based assay of estrogen receptor using 12-oxo-9(11)-dehydroestradiol-17 ?. Anal. Biochem. (1986) 159(2):336-348.
74. MIKSICEK RJ, CARLSON KE, HWANG KJ, KATZENELLENBOGEN JA: Studies using fluorescent tetrahydrochrysene estrogens for in situ visualization of the estrogen receptor in living cells. Mol. Endocrinol. (1995) 9(5):592-604.
75. VAN HOORN WP: Identification of a second binding site in the estrogen receptor. J. Med. Chem. (2002) 45(3):584-589.
76. BOLOGA CG, REVANKAR CM, YOUNG SM et al.: Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat. Chem. Biol. (2006) 2(4):207-212.
77. ZHANG JH, CHUNG TD, OLDENBURG KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. (1999) 4(2):67-73.
78. KUCKUCK FW, EDWARDS BS, SKLAR LA: High throughput flow cytometry. Cytometry (2001) 44(1):83-90.
79. RAMIREZ S, AIKEN CT, ANDRZEJEWSKI B, SKLAR LA, EDWARDS BS: High-throughput flow cytometry: validation in microvolume bioassays. Cytometry A (2003) 53(1):55-65.
80. EDWARDS BS, OPREA T, PROSSNITZ ER, SKLAR LA: Flow cytometry for high-throughput, high-content screening. Curr. Opin. Chem. Biol. (2004) 8(4):392-398.
81. OLAH M, MRACEC M, OSTOPOVICI L et al.: Wombat: world of molecular bioactivity. Opreati (Ed) In Chemoinformatics in drug discovery. Wiley-VCH, USA 223-239 (2005).
82. SHAUL PW: Regulation of endothelial nitric oxide synthase: location, location, location. Ann. Rev. Physiol. (2002) 64:749-774.
83. PAPPAS TC, GAMETCHU B, WATSON CS: Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J. (1995) 9(5):404-410.
84. SCHIAFFINO MV, D'ADDIO M, ALLONI A et al.: Ocular albinism: Evidence for a defect in an intracellular signal transduction system. Nat. Genet. (1999) 23(1):108-112.
85. MARRACHE AM, GOBEIL F, ZHU T, CHEMTOB S: Intracellular signaling of lipid mediators via cognate nuclear G protein-coupled receptors. Endothelium (2005) 12(1-2):63-72.
86. ZHU Y, RICE CD, PANG Y, PACE M, THOMAS P: Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes. Proc. Natl. Acad. Sci. USA (2003) 100(5):2231-2236.
87. ZHU Y, BOND J, THOMAS P: Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor. Proc. Natl. Acad. Sci. USA (2003) 100(5):2237-2242.
88. PELUSO JJ, PAPPALARDO A, LOSEL R, WEHLING M: Progesterone membrane receptor component 1 expression in the immature rat ovary and its role in mediating progesterone's anti-apoptotic action. Endocrinology (2006).
89. HEINLEIN CA, CHANG C: The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol. Endocrinol. (2002) 16(10):2181-2187.
90. GAMETCHU B, WATSON CS: Correlation of membrane glucocorticoid receptor levels with glucocorticoid-induced apoptotic competence using mutant leukemic and lymphoma cells lines. J. Cell. Biochem. (2002) 87(2):133-146.
91. WATSON CS, GAMETCHU B: Membrane estrogen and glucocorticoid receptors-implications for hormonal control of immune function and autoimmunity. Int. Immunopharmacol. (2001) 1(6):1049-1063.
92. CHUN TY, PRATT JH: Nongenomic renal effects of aldosterone: dependency on no and genomic actions. Hypertension (2006) 47(4):636-637.
93. SCHMIDT BM, SAMMER U, FLEISCHMANN I, SCHLAICH M, DELLES C, SCHMIEDER RE: Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension (2006) 47(4):650-655.
94. http://www.mesaac.com This is the company website for Mesa Analytics and Computing LLC. One of their products, the Fingerprint Module, encodes the MDL 320 keys.
95. http://www.daylight.com/This is the company website for Daylight Chemical Information Systems. One of their products, the Daylight Toolkit package, encodes the Daylight 2048 fingerprints.
96. http://www.eyesopen.com/products/applicati ons/omega.html This is a direct link to OMEGA, one of the products from OpenEye Scientific Software. OMEGA provides multi-conformer (3D) structures from two-dimensional input chemical structures.